Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of Ga-68-PSMA-11 (n = 2) and Ga-68-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of Ga-68-PSMA-11 (PCa) or 1.2 MBq/Kg of Ga-68-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 mu Sv per procedure (range 26-40 mu Sv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of Ga-68-PSMA-11 and Ga-68-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis.

First Live-Experience Session with PET/CT Specimen Imager: A pilot analysis in Prostate Cancer and Neuroendocrine Tumor / L. Muraglia, F. Mattana, L.L. Travaini, G. Musi, E. Bertani, G. Renne, E. Pisa, M.E. Ferrari, U. Fumagalli Romario, O. De Cobelli, N. Fusco, F. Ceci. - In: BMC MEDICAL IMAGING. - ISSN 1471-2342. - 11:2(2023), pp. 645.1-645.9. [10.3390/biomedicines11020645]

First Live-Experience Session with PET/CT Specimen Imager: A pilot analysis in Prostate Cancer and Neuroendocrine Tumor

G. Musi;O. De Cobelli;N. Fusco;F. Ceci
Ultimo
2023

Abstract

Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of Ga-68-PSMA-11 (n = 2) and Ga-68-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of Ga-68-PSMA-11 (PCa) or 1.2 MBq/Kg of Ga-68-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 mu Sv per procedure (range 26-40 mu Sv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of Ga-68-PSMA-11 and Ga-68-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis.
PET; PET/CT; PET/CT specimen imager; radio-guided surgery
Settore MED/24 - Urologia
2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
preprints202212.0444.v2.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 655.66 kB
Formato Adobe PDF
655.66 kB Adobe PDF Visualizza/Apri
biomedicines-11-00645-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.95 MB
Formato Adobe PDF
1.95 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/953144
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact